News | Leads Implantable Devices | May 13, 2019

BioTrace Medical's Tempo Lead Obtains CE Mark for Temporary Intracardiac Pacing

Temporary pacing lead designed to reduce intraprocedural complications following TAVR and TMVR

BioTrace Medical's Tempo Lead Obtains CE Mark for Temporary Intracardiac Pacing

May 13, 2019 — BioTrace Medical Inc. announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing.

BioTrace Medical’s Tempo Temporary Pacing Lead is designed for safer, more secure and stable pacing to reduce intraprocedural complications, including perforation and valve embolization. In addition, the Tempo Lead allows patients to ambulate sooner after procedures such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve replacement (TMVR), accelerating recovery times, and enabling patient transfer directly to a step-down or telemetry unit instead of an ICU or CCU.

Cleared by the U.S. Food and Drug Administration (FDA) in October 2016, the Tempo Lead’s design, featuring novel retractable stabilizer loops and a soft tip, mitigates the risks of dislodgment and perforation and ensures stability during rapid pacing.

In a U.S. multi-center retrospective study1 of 269 patients led by Columbia University Medical Center and presented at the American College of Cardiology’s Annual Scientific Session in 2018, the Tempo Lead was successfully placed in 98.1 percent of the cases with no cardiac perforations, pericardial effusions or sustained device-related arrhythmias, and only a 0.8 percent loss of pace capture. The Tempo lead was left in place post-procedure in 71.6 percent of the cases, of which 84.1 percent mobilized out of bed while maintaining stable pace capture with no dislodgment. The study confirmed the Tempo Lead is safe and effective for temporary cardiac pacing, provides stable peri- and post-procedural pacing support, and facilitates post-procedure ambulation, which can safely allow direct transfer to step-down or telemetry units with no ICU time required, reducing length of stay.2

In addition, the Tempo Lead allows watchful waiting after procedures, potentially avoiding permanent pacemaker implantation in patients with transient conduction disturbances that may resolve on their own with time. The European Society of Cardiology cardiac pacing guidelines recommend a seven-day period of clinical observation to assess the type and significance of disturbances before permanent pacemaker implantation,3 a period of time in which the need for safe and stable temporary pacing allowing ambulation is even more important. These benefits are increasingly significant as TAVR procedures expand to intermediate and low-risk patients.

The design of conventional temporary pacing leads can cause serious complications, including perforation of the heart wall, which may lead to potentially life-threatening compression of the heart. Additionally, conventional leads can easily dislodge from the heart, often resulting in loss of pacing with serious consequences for the patient. As a result, patients are routinely limited to bed rest for the duration of temporary pacing, delaying ambulation and thereby increasing length of stay in costly hospital units such as intensive care.

For more information: www.biotracemedical.com

References

1. Nazif, T et al. Analysis of the Initial United States Experience with the BioTrace Tempo Temporary Pacing Lead in Transcatheter Aortic Valve Replacement (TAVR) and Other Cardiac Procedures, Journal of the American College of Cardiology, Volume 71, Issue 11, Supplement, 2018, Page A1285, ISSN 0735-1097, https://doi.org/10.1016/S0735-1097(18)31826-6

2. Yakubov SR. TCT 2017: How to Manage Conduction Abnormalities and Pacemaker Implantation (temporary and permanent) After TAVR. November 1, 2017, https://www.tctmd.com/videos/how-to%C2%85-manage-conduction-abnormalities-and-pacemaker-implantation-temporary-and-permanent-after-tavr.f1c14ee9364243e0abd8e604545cda07

3. Michele Brignole et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy, European Heart Journal (2013) 34, 2281–2329 doi:10.1093/eurheartj/eht150

Related Content

SpectraWave is developing a a new intravascular imaging system that combines two currently available modalities. This likely includes optical coherence tomography (OCT), left, which can define structures within the vessel and vessel wall.  Near infrared spectroscopy (NIRS), right, enables a spectral chemical analysis of the vessel walls to show areas of high lipid content, and specifically can identify lipid-core plaques that are associated with heart attack-causing plaque ruptures.

News | Cath Lab | February 16, 2021
February 16, 2021 – SpectraWave Inc.
Videos | Cath Lab | February 04, 2021
Cindy Grines, M.D., MSCAI, FACC, president
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over